CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (46,383)	$ (74,532)
Adjustments to reconcile net loss to cash flows used in operating activities:
Amortization of intangible assets	1,845	1,230
Depreciation of property and equipment	109	127
Amortization of debt discount	430	363
Non-cash interest expense	728
Loss on extinguishment of debt	3,810	0
Stock-based compensation	3,711	2,814
Change in fair value of derivative liability		45,164
Changes in operating assets and liabilities:
Accounts receivable and other current assets	(10,681)	(770)
Inventory	(2,280)
Accounts payable and accrued expenses	3,481	3,415
Right-of-use assets and operating lease liabilities	47	0
Deferred revenue	(30)	(505)
Deferred rent		27
Net cash used in operating activities	(45,213)	(22,667)
Cash flows from investing activities:
Acquisition of Icon Bioscience Inc., net of cash acquired	0	(16,780)
Purchases of property and equipment	(207)	(153)
Net cash used in investing activities	(207)	(16,933)
Cash flows from financing activities:
Proceeds from issuance of stock, net of issuance costs	20,755	34,471
Proceeds from exercise of warrants		28,863
Proceeds from issuance of long-term debt	50,000	20,000
Payment of debt issue costs	(1,341)	(1,347)
Payment of long-term debt principal	(20,000)
Payment of extinguishment of debt costs	(2,716)
Net settlement of stock units to satisfy statutory tax withholding	(87)
Proceeds from exercise of stock options	308	503
Payment of contingent development milestone	(15,000)
Net cash provided by financing activities	31,919	82,490
Effect of foreign exchange rate changes on cash and cash equivalents	0	(2)
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,501)	42,888
Cash, cash equivalents and restricted cash at beginning of period	45,411	13,026
Cash, cash equivalents and restricted cash at end of period	31,910	55,914
Supplemental cash flow information:
Cash interest paid	3,574	841
Supplemental disclosure of non-cash investing and financing activities:
Accrued development milestone		15,000
Accrued term loan exit fee	$ 3,000	1,200
Fair value of second tranche purchase liability		4,734
Fair value of warrants issued with debt		355
Fair value of second tranche warrants		$ 18,165